Martin Rabel | Global Sales Specialist | Biopharma Services
Cytiva

Dr. Martin Rabel is a dynamic thought leader in the biopharma industry, currently serving as the Global Sales Specialist - Biopharma Services at Cytiva. In this role, Dr. Rabel leverages his extensive expertise to drive global sales and support biopharma clients, focusing on developing, manufacturing, and commercializing cutting-edge lipid nanoparticle (LNP) and genomic medicine technologies. With a robust background in pharmaceutical sciences, Dr. Rabel obtained his pharmaceutical license and postgraduate diploma from Friedrich-Schiller-University Jena, where he specialized in Bacterial Nanocellulose (BNC) nanoparticles for gene delivery applications. His Ph.D. research further honed his skills in developing animal-free simulation models for complex diagnostic nanoparticles (IONP) and other nanomedicines. Since joining Precision NanoSystems (now Cytiva) in 2019 as a Field Application Scientist, Dr. Rabel has been instrumental in advancing the company's microfluidic NanoAssemblr platform and gene delivery reagents. His leadership in formulation development, optimization, and scale-up, including GMP manufacturing, has been pivotal in translating disease biology insights into non-viral genomic medicines. Dr. Rabel's current focus is on driving the adoption and success of Cytiva's BioPharma Services, particularly in the LNP and genomic medicine space. This includes providing comprehensive development and manufacturing (CDMO) services to support clients in bringing their therapies from concept to clinic. His work is crucial in advancing genomic medicines for infectious diseases, cancer, and rare diseases, making significant contributions to the field and supporting clients worldwide in their quest to develop innovative therapies. In addition to his role at Cytiva, Dr. Rabel serves as a member of the mRNAVAC Working Party at the European Directorate for the Quality of Medicines & HealthCare (EDQM). In this capacity, he helps advance regulatory standards for RNA-LNP, contributing to the development of robust guidelines that ensure the safety and efficacy of these innovative therapies.